EDAP TMS reports Q4 EPS (25c), consensus (16c)

Reports Q4 revenue $21.88M, consensus $21.28M. “We experienced strong global demand for Focal One Robotic HIFU as demonstrated by our 2025 results,” said Ryan Rhodes, CEO. “In the fourth quarter, we achieved a quarterly record of net system placements of 15, of which 14 were cash sales and one was an operating lease. We also experienced robust Focal One procedure growth in the U.S., which reflects a growing number of urologists utilizing focal therapy to manage early-stage prostate cancer. We believe demand for Focal One is being driven by growing clinical data, the versatility and adaptability of the Focal One platform, and increasing patient demand for a non-invasive treatment option designed to help preserve urinary and sexual function.”